A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 679 participants.

Also called NCT05013229

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 679 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05013229
  • EudraCT 2020-005309-18
  • jRCT jRCT2051210127
Other papers using this trial's data
  • Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial The lancet. Diabetes & endocrinology, 2025-07 DOI, PubMed 40482670

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Czechia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Poland, Slovenia, South Africa, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05013229. Randomized; no masking; primary purpose treatment. Start 2021-11-30 (actual); primary completion 2023-11-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
IcoSema
Intervention (Drug)
Insulin glargine
Intervention (Drug)
insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05013229
Content hash
fcd4cd6714d6f56bdd8078432a1f03bc96fce22e00774baf8ba9ff2e568bdd29